Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 6/20 | 0.51 |
| ▸ | MMP9 | P14780 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286243 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL2640824 | 0.90 | HDAC7 (0.53) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL2640823 | 0.90 | HDAC7 (0.53) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL11686163 | 0.89 | HDAC1 (0.59) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL7080833 | 0.86 | ALDH1A1 (0.58) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL12605262 | 0.85 | ALDH1A1 (0.54) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL30307799 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL8897056 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL11656910 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CA12CA9MMP2MMP9 | |
| SCHEMBL8898810 | 0.82 | ALDH1A1 (0.70) | ALDH1A1CA12CA9MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107102083-B | PHBA process impurity detection method | 成都丽凯手性技术有限公司 | 2020-09-15 | — | — | CN | claimed |
| CN-111201226-B | Cyclic substituted imidazo [4,5-c ] quinoline derivatives | 辉瑞大药厂 | 2022-07-22 | — | — | CN | disclosed |
| EP-3592740-B1 | CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | PFIZER (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11161844-B2 | Cyclic substituted imidazo[4,5-c]quinoline derivatives | PFIZER INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161844-B2 | Cyclic substituted imidazo[4,5-c]quinoline derivatives | PFIZER INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3350178-B1 | NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3350178-B1 | NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-108137586-B | Novel imidazo [4,5-c ] quinoline and imidazo [4,5-c ] [1,5] naphthyridine derivatives as LRRK2 inhibitors | 辉瑞大药厂 | 2021-04-13 | — | — | CN | disclosed |
| CN-107102083-B | PHBA process impurity detection method | 成都丽凯手性技术有限公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-111201226-A | Cyclic substituted imidazo [4,5-c ] quinoline derivatives | 辉瑞大药厂 | 2020-05-26 | — | — | CN | disclosed |
| US-6001867-A | HYPOGLYCEMIC AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999058521-A1 | 11-ARYL-BENZO[B]NAPHTHO[2,3-D]FURANS AND 11-ARYL-BENZO[B]NAPHTHO[2,3-D]THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| US-4360665-A | 4\"-N-(Substituted)-apramycin antibiotic derivatives and intermediates therefor | ELI LILLY AND COMPANY (US) | 1982-11-23 | — | — | US | disclosed |
| US-4125706-A | Novel process for the preparation of 1-N-(alpha-substituted-omega-aminoacyl)-3'-deoxyribostamycin | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1978-11-14 | — | — | US | disclosed |
| US-4107424-A | ANTIBACTERIAL | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1978-08-15 | — | — | US | disclosed |
| US-4104372-A | ANTIBACTERIAL | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1978-08-01 | — | — | US | disclosed |
| US-4008218-A | MULTISTAGE | MEIJI SEIKI KAISHA, LTD. (JA) | 1977-02-15 | — | — | US | disclosed |
| US-4008362-A | ANTIBIOTIC | MEIJI SEIKA KAISHA, LTD. (JA) | 1977-02-15 | — | — | US | disclosed |
| US-4001208-A | DERIVATIVE OF AN AMINOGLYCOSIDIC ANTIBIOTIC | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYO KAI (JA) | 1977-01-04 | — | — | US | disclosed |
| US-3948882-A | ANTIBIOTIC | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161844-B2 | Cyclic substituted imidazo[4,5-c]quinoline derivatives | LRRK2, PARK7, BRCA1 | ALDH1A1 2211/4885CA12 4822/4885CA9 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.